Related Experiment Video
Updated: Apr 12, 2026

Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes
Published on: June 28, 2024
Quantifying the lifetime economic impact of pediatric oral nutritional supplements
Kyi-Sin Than1, Khounish Sharma1, Kirk W Kerr2
1FTI Consulting, Center for Healthcare Economics and Policy, Los Angeles, CA, USA.
Insights
Oral nutritional supplements (ONS) for children at risk of undernutrition in India significantly improve health and economic outcomes. This intervention offers a substantial return on investment, highlighting its value in public health strategies.
Area of Science:
- Public Health
- Health Economics
- Pediatric Nutrition
Background:
- Pediatric malnutrition is a critical global health issue, especially in low- and middle-income countries.
- This study evaluates the economic impact of pediatric oral nutritional supplements (ONS) for undernourished children.
Purpose of the Study:
- To quantify the lifetime, per-person economic impact of pediatric ONS for children at risk of undernutrition in India.
- To assess the health and economic benefits of ONS interventions.
Main Methods:
- A decision tree model was used to analyze health and economic outcomes in Indian children.
- Key outcomes included height-for-age Z-score (HAZ), morbidity, lifetime earnings, and quality-adjusted life-years (QALYs).
- A lifetime perspective with a 3% discount rate was applied.
Main Results:
- Pediatric ONS increased mean HAZ by 0.125, improving health outcomes by 0.28 QALYs ($1,019 per person).
- Lifetime economic earnings increased by $471 per person.
- The total lifetime incremental value was $1,281 per person, with an estimated 5.63% internal rate of return.
Conclusions:
- Pediatric ONS are predicted to enhance both quality-of-life and economic prospects for undernourished Indian children.
- Integrating nutritional interventions like ONS into public health strategies is crucial for addressing childhood undernutrition.
- Findings have significant implications for global health policy and nutritional interventions.
Introduction:
Pediatric malnutrition is a significant global public health challenge, particularly in low- and middle-income countries. This study quantifies the lifetime, per-person economic impact of pediatric oral nutritional supplements (ONS) for children at risk of undernutrition.
Methods:
A decision tree model was constructed to assess the impact of pediatric ONS on health and economic outcomes of children at risk for undernutrition in India. Outcomes included changes in mean childhood height-for-age Z-score (HAZ), morbidity, and lifetime earnings. Total net incremental value was modeled as the sum of future earnings and quality-of-life benefits net the intervention costs. The model used a lifetime perspective at the individual level, discounted at 3%.
Results:
Compared to the standard of care, pediatric ONS use increased mean HAZ by 0.125. This increase in height was projected to improve health outcomes by 0.28 in quality adjusted life-years (valued at $1019 per person) and lifetime economic earnings by $471 per person. The total lifetime incremental value of ONS was $1281 per person net of lifetime pediatric ONS costs of $210. The model estimated a 5.63% internal rate of return on incremental earnings from pediatric ONS. The model was most sensitive to changes in HAZ scores and the height-wage premium.
Discussion:
Pediatric ONS is predicted to improve both quality-of-life and economic outcomes for children at risk of undernutrition in India. These findings underscore the value of integrating nutritional interventions into public health strategies to address childhood undernutrition, with implications for global health policy.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
